The QualityStocks Daily Wednesday, September 5th, 2018

Today's Top 3 StockMarketWatch

MarketBeat (DRWIQ) +900.00%

StockMarketWatch (PRQR) +120.75%

TopPennyStockMovers (PSIQ) +43.75%

The QualityStocks Daily Stock List

Propanc Biopharma, Inc. (PPCB)

NetworkNewsWire, Penny Stock Hub, Wallmine, InvestorsHangout, Stockopedia, Wallet Investor, Stockwatch, InvestorsHub, Simply Wall St, StockInvest.us, and Investing News reported on Propanc Biopharma, Inc. (PPCB), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Propanc Biopharma, Inc. is a clinical stage Biopharmaceutical Company based in Australia. It centers on the development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian, and colorectal cancers. Propanc has developed a formulation of anti-cancer compounds, which exert manifold effects designed to control or prevent tumors from recurring and spreading throughout the body.

Propanc Biopharma is developing a long-term therapy based on a pancreatic proenzyme formulation to prevent tumour recurrence and metastasis. The Company’s lead product is PRP. This is a novel, patented, formulation consisting of two proenzymes mixed in a synergetic ratio. PRP is a solution for once daily intravenous administration of a combination of two pancreatic proenzymes, trypsinogen and chymotrypsinogen, for the treatment of pancreatic cancer.

Propanc Biopharma has received Orphan Drug Designation (ODD) from the Food and Drug Administration (FDA) for the use of PRP. The approved indication is one of the most lethal malignancies with a median survival of 6 months and a 5-year survival rate of less than 5 percent.

After wide-ranging laboratory research and a limited amount of human testing, the Company has evidence that PRP reduce cancer cell growth via promotion of cell differentiation; enhances cell adhesion and may suppress metastasis progression; and has no serious side effects and improves patient survival. In addition, the FDA granted Orphan Drug Designation status to PRP for the treatment of pancreatic cancer.

Recently, Propanc Biopharma announced that it entered National Phase for two of its important patent applications from its intellectual property (IP) portfolio. The first patent application, which entered National Phase in July, describes a method to eradicate cancer stem cells. A second patent application, encompassing proenzyme compositions for the treatment of solid tumors, recently completed National Phase entry mid-July.

National Phase is a process where applicants file a patent application in each individual jurisdiction or country, according to where IP protection is sought. Propanc filed the patent applications in all major international jurisdictions including the United States and Europe, and key jurisdictions in Asia and South America. Both cover its lead product candidate, PRP.

Propanc Biopharma's Chief Scientific Officer, Dr. Julian Kenyon, said, "I am excited to reach this stage where we are entering National Phase for another two key patent applications from our IP portfolio, one covering important composition claims for the PRP formulation, and another describing an innovative method to eradicate cancer stem cells from solid tumors. We have been working with PRP and cancer stem cells for several years and our pre-clinical studies demonstrate that PRP appears to have a significant effect on killing these cells off, which are the main drivers of cancers. This is highly important because killing cancer stem cells reduces the risk of tumor recurrence, clinically."

Propanc Biopharma, Inc. (PPCB), closed Wednesday's trading session at $0.2599, up 42.80%, on 33,723,000 volume with 3,862 trades. The average volume for the last 60 days is 5,652,418 and the stock's 52-week low/high is $0.0039/$0.77.

chart

Molori Energy, Inc. (MOLOF)

Awesome Stock Picks, Zacks, OTC Markets, Stockhouse, Streetwise Reports, InvestorsHub, and MarketWatch reported on Molori Energy, Inc. (MOLOF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

An oil and gas production enterprise, Molori Energy, Inc. has current operations in the Texas Panhandle West Field. Its operating team based in Borger, Texas has extensive experience in the oil and gas industry in the Texas Panhandle. Molori Energy's business model is to deliver sustainable growth in shareholder value through centering on exploiting its existing reserves, commercializing and developing discoveries, and pursuing selective acquisitions.

Molori Energy has its corporate office in Vancouver, British Columbia. The Company previously went by the name Taipan Resources, Inc. It changed its name to Molori Energy, Inc. in January of 2017. The Company lists on the OTC Markets.

Molori Energy’s strategy has been to engage in low-risk well reactivations in the Texas Panhandle to produce steady cash flows. Greater than 60 wells have been reactivated to date. These are producing from the prolific Brown Dolomite formation. Molori owns a 25 percent Working Interest (WI) in certain leases positioned in the bifurcated Texas panhandle, operated by its Texas-based partner Ponderosa Energy, LLC.

Molori has 165 producing (PDP) wells and an inventory of about 202 non-producing wells (PDNP) for a total of 367 wells. The Company is working to RTP (Return to Production) the PDNP wells through performing simple re-works or re-completions.

In February 2018, Molori Energy announced a commercial oil discovery on its acreage in Moore County, Texas. The "Thompson 23-1R" well, operated by Molori, is a northern step-out well drilled in December 2017. The Thompson 23-1R well is directly north of the active development area of Adams Affiliates.

Molori Energy earlier signed an LOI (Letter of Intent) to purchase a 100 percent WI of which the Company will be the operator of record in an additional roughly 5,100 gross acres of land in Moore, Potter, and Carson Counties, north Texas. With the agreement, Molori is to hold a 100 percent WI in the leases, some of which border lands where Adams Affiliates of Tulsa, Oklahoma is now developing oil and gas production from the Red Cave formation. The roughly 5,100 acres are now held by production (HBP). They contain a 75 percent NRI (Net Royalty Interest).

In July, Molori Energy provided an update concerning its operations in Moore County and Hutchinson County, Texas. The Company announced on May 7, 2018, the first of two Letters of Intent (LOIs) to acquire a 100 percent Working Interest (WI) in roughly 30,000 acres with access to the Red Cave and other formations.

The acreage, in Moore, Potter, Carson and Hutchinson counties, is HBP (Held By Production). It includes 8 currently-producing wells. The agreement calls for the payment of USD $1,700,000 in cash on closing. Molori announced on May 22, 2018, the second LOI for the purchase of a 100 percent WI in an additional 5,100 acres in the Red Cave formation.

Molori Energy, Inc. (MOLOF), closed Wednesday's trading session at $0.0946, down 1.46%, on 4,535 volume with 4 trades. The average volume for the last 60 days is 48,089 and the stock's 52-week low/high is $0.0842/$0.5066.

chart

Tautachrome, Inc. (TTCM)

MarketWatch and InvestorsHub reported on Tautachrome, Inc. (TTCM), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Tautachrome, Inc. is an emerging growth enterprise in the developing digital imagery technology sector. It is a developer of software applications for trustable and engageable digital pictures and videos. The Company’s chief priority is developing its branded KlickZie platform. An Internet technology development business, Tautachrome is headquartered in Oro Valley, Arizona and has operations in the United States and Australia.

The KlickZie platform will turn smartphones into trusted imagers. This means the pictures and videos they capture can be verified as original, untampered, and un-photoshopped. Additionally, the KlickZie platform creates imagery that is interactive and engageable.

The KlickZie platform will serve as the world’s first imagery-based social website network. Through clicking or tapping on a KlickZie'd image, users can communicate with the image's author or others presently looking at the image, in an engaging way.

Basically, KlickZie is an image verification service for smartphones. It brings trust back to digital imagery. In addition, KlickZie turns the smartphone into a reliable image source. Smartphone users download KlickZie’s free software to take their pictures and videos.

KlickZie pictures and videos are invisibly marked, stored in the KlickZie cloud, and guaranteed free from manipulation. The cloud will certify the authenticity of any KlickZie picture or video.

Tautachrome also has pioneering patents pending. These include Talk-to-the-Picture social networking and the abovementioned trustable imagery-based interaction.

Tautachrome is establishing a development team of providers to develop a blockchain based cryptocurrency ecosystem with a cryptotoken designated “KLK”. It will be the currency of the KlickZie community internationally.

This will permit KlickZie users to monetize their pictures and videos. As a result, it will enable the buying, selling, and licensing of KlickZie pictures and videos everywhere.

Recently, Tautachrome announced that it hired the Pryor Cashman law firm in New York to lead its work to register its KLK cryptotoken sale with the Securities and Exchange Commission (SEC). Mr. Ali Panjwani with support from his colleagues Mr. Jeff Alberts and Mr. Mike Campoli is leading the Pryor Cashman work team. This team has considerable cryptotoken knowledge. In addition, it has significant experience with SEC registration. This includes past employment with the SEC in this area.

Tautachrome Chief Executive Officer, Dr. Jon N Leonard, said, “I have directed the Pryor Cashman team to work with the SEC’s crypto currency task force to ensure that our vision for a KLK cryptotoken-based ecosystem, able to monetize the world’s smartphone imagery becomes a reality, and that it is fully compliant with SEC regulations. We appear to be breaking new ground in this work. But I believe that the social and economic potential of this effort is so great, that every effort is justified.”

Tautachrome, Inc. (TTCM), closed Wednesday's trading session at $0.00615, up 2.50%, on 399,415 volume with 6 trades. The average volume for the last 60 days is 264,676 and the stock's 52-week low/high is $0.0032/$0.028.

chart

THC BioMed Intl. Ltd. (THCBF)

Stockhouse, TipRanks, Insider Financial, Morningstar, InvestorsHub, YCharts, Market Screener, Barchart, MarketWatch, Wallet Investor, GuruFocus, and TradingView reported on THC BioMed Intl. Ltd. (THCBF), and we also report on the Company, here at the QualityStocks Daily Newsletter.

THC BioMed Intl. Ltd. is an ACMPR (Access to Cannabis for Medical Purposes Regulations) Licensed Producer and Canada's largest supplier of legal Cannabis Genetics. The Company also produces and sells dried and fresh marijuana and cannabis oil for medical purposes. THC currently offers over two dozen different genetic strains for sale. THC BioMed is based in Kelowna, British Columbia. The Company’s shares trade on the OTC Markets Group’s OTCQB.

THC BioMed has the largest assortment of genetic strains available in Canada for home growers. It has developed strains with a distinct herbal odor. This results in a product that exhibits a less pungent marijuana smell when smoked.

THC BioMed has its Clone Shipper acquisition. It is laying the groundwork in preparation for becoming the wholesaler of choice of live clones to the expected home growers' market. The patented design of the Clone Shipper 3.0 containers allows for an LED light to keep the clone in the growing vegetative stage for 12 to 24 hours during shipment. The Company is using the newly designed Clone Shipper 3.0 containers to ship live cannabis plants across Canada.

THC BioMed has created THC2GO Dispensaries. THC, through its wholly-owned subsidiary "THC2GO Dispensaries", began the application process to become a cannabis retailer in the Province of Manitoba. Moreover, THC2GO Dispensaries’ intention is to apply for retail outlets in each Canadian province that permits private cannabis retail outlets.

This past February, THC BioMed announced that it entered into a Letter of Intent (LOI) to purchase a Farm and Greenhouses in the Niagara Region of Ontario. The new property consists of 8 1/2 acres. It has roughly 7 acres of growing space, including 70,000 square feet of greenhouse space.

In late June, THC BioMed announced that it will purchase an additional strata lot in the industrial complex in Kelowna it now occupies and where more lots were recently purchased on June 12, 2018. The additional lot will be used for production purposes. The Company is purchasing this property as part of its expansion plan because of high demand for its products.

THC BioMed has been selected by the province to supply British Columbians with adult-use cannabis. The Company entered into an agreement by way of its wholly-owned subsidiary, THC BioMed Ltd. to supply non-medical cannabis to the B.C. Liquor Distribution Branch following legalization. With this agreement, B.C. agrees to purchase about 2,390,200 grams of cannabis from THC BioMed in the first 12 months of legalization at the prices set by the province. The cannabis will be in 19 different products and in the form of dried flower, pre-rolled, as well as oil.

THC BioMed has developed a cannabis beverage, which imitates alcohol in that the uplifting and energizing effects of the cannabis is felt by the consumer in a short period of time. The Company believes that this beverage is a solution to a significant problem with cannabis beverages and edibles, as present products cause fatigue and drowsiness. Production and sale of the beverage is not now legal in Canada, it may become legal at a later date. THC BioMed intends to patent the formula.

THC BioMed Intl. Ltd. (THCBF), closed Wednesday's trading session at $0.77062, down 3.67%, on 102,248 volume with 128 trades. The average volume for the last 60 days is 56,852 and the stock's 52-week low/high is $0.3788/$2.65.

chart

DiaMedica Therapeutics, Inc. (DMCAF)

Penny Stock Hub, Business Insider, StreetInsider, MarketWatch, Stockhouse, GuruFocus, Zacks, OTC Markets, Barchart, Marketwired, The Street, and WeeklyHub reported on DiaMedica Therapeutics, Inc. (DMCAF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

DiaMedica Therapeutics, Inc. concentrates on improving the lives of patients with neurological and kidney diseases associated with low KLK1 levels. The Company is developing inventive treatments where there is significant unmet clinical need or where no present therapies are available with a focus on neurological and kidney diseases. A clinical stage biopharmaceutical enterprise, the Company previously went by the name DiaMedica, Inc.  It changed its corporate name to DiaMedica Therapeutics, Inc. in December of 2016. DiaMedica is based in Minneapolis, Minnesota.

DiaMedica Therapeutics is developing DM199. This is a recombinant (synthetic) human protein for patients suffering from neurological and kidney diseases. DM199 has undergone clinical testing, which demonstrates its exceptional safety as a potential treatment for an array of disorders. DiaMedica is positing DM199 for the treatment of diabetic nephropathy and post-insult treatment from acute ischemic stroke (AIS).

The Company is presently conducting a clinical trial designed to identify a dose of DM199 that is comparable to the human urinary and porcine approved versions in Asia. The results of this study will direct dosing for Phase II and Phase III clinical trials.

DiaMedica Therapeutics advanced its deep understanding of DM199 in 2017. In addition, it moved into the second phase of clinical trials. The DM199 Phase 2 REMEDY stroke study began in the fall of 2017. Moreover, the DM199 Phase 1B bridging study for acute ischemic stroke dosing trial with DM199 was completed.

This is a major milestone. It identified a therapeutic dose of DM199, which pharmaceutically matches the crude form of the protein, named Kailikang®.  Kailikang® is approved in Asia. It has been used to treat more than 400,000 stroke patients.

Additionally, DiaMedica has identified chronic kidney disease (CKD) caused by Type 1 diabetes as the primary indication for its first kidney disease trial. It announced in February 2018 the first patient enrollment, at the Royal Melbourne Hospital, Melbourne Australia, in its Phase 2 REMEDY trial assessing the safety, tolerability and markers of therapeutic efficacy of DM199 (recombinant human KLK1) in patients suffering from acute ischemic stroke.

Today, DiaMedica Therapeutics announced the recent appointment of Harry Alcorn Jr. Pharm.D. as Chief Medical Officer. Dr. Alcorn will oversee worldwide clinical development and regulatory initiatives for DiaMedica.  He has more than three decades of clinical research experience working with public and private biotechnology and pharmaceutical companies in studies of kidney diseases and diabetic, hepatic and cardiovascular patients.

Dr. Alcorn has served as Principal Investigator or Sub Investigator in greater than 450 clinical studies. He has also assisted numerous biotechnology and pharmaceutical companies in negotiating protocols and presenting results to the Food and Drug Administration (FDA).

DiaMedica Therapeutics, Inc. (DMCAF), closed Wednesday's trading session at $0.3771, up 5.40%, on 208,500 volume with 28 trades. The average volume for the last 60 days is 252,773 and the stock's 52-week low/high is $0.188/$0.6887.

chart

EnviroLeach Technologies, Inc. (EVLLF)

Dividend Investor, OTC Markets, Barchart, Investopedia, Marketwired, Streetwise Reports, MarketWatch, Stockhouse, GuruFocus, 4-Traders, Investors Hub, and Stock Market Revolution reported on EnviroLeach Technologies, Inc. (EVLLF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

EnviroLeach Technologies, Inc. is a technology business and near-term gold producer. The Company engages in the development and commercialization of environmentally-friendly formulas and technologies for the treatment of materials in the mining and E-Waste sectors. Its goal is to become a top gold producer through the “Urban-Mining” of end-of-life electronics and be a significant player in the extraction of precious metals in the traditional mining space. EnviroLeach Technologies is based in Burnaby, British Columbia.

Employing its proprietary non-cyanide, non-acid based process, EnviroLeach extracts precious and base metals from ores, concentrates, and E-Waste using only Food and Drug Administration (FDA) approved additives. The Company developed a unique, cost-effective and environmentally-friendly alternative to cyanide and strong-acid based processes now used for the extraction of precious metals from mineral ores, concentrates, as well as E-Waste.

This process is similar to the standard cyanide vat leaching circuits utilized today. However, it is much safer and simpler. The patent-pending EnviroLeach formula comprises combining five non-toxic, FDA approved dry ingredients with ambient temperature water.

In 2017, EnviroLeach Technologies and Mineworx Technologies successfully advanced their proven chemical formulas and mechanical processes with a number of additional proprietary and patent-pending breakthroughs. The new discoveries include major enhancements to the proven EnviroLeach E-Waste process regarding improved leach kinetics, improved recoveries, metal complex stability, element selectivity, metal precipitation and the reusability of the main solution.

Additionally, the two companies completed a series of successful pilot scale tests throughout 2017. They completed the design, engineering and construction of the initial production scale, 10 tonne per day E-Waste processing plant that was installed on-schedule and on-budget at the Memphis, Tennessee facility.

The EnviroLeach reagent is well suited for the leaching of gold in an agitated or vat leach type process. This includes the treatment of whole ores, gravity concentrates, flotation concentrates, and E-Waste. This segment of the market represents most of the worldwide gold produced.

This past July, EnviroLeach Technologies announced that new upgrades and enhancements to the EnviroLeach process yielded positive results in a series of bulk tests. The modifications and enhancements to the EnviroLeach process (that included the addition of a proprietary 3 stage concentration process and minor formula modifications) delivered major improvements in performance and recoveries.

Moreover, EnviroLeach’s partner, Mineworx Technologies, has leased a 13,674 sq. ft. facility in Vancouver (Surrey), British Columbia to construct and assemble a 20 tonne per day E-Waste concentrate plant. Testing was scheduled to commence on September 1st with the start of half-scale production on October 1st.

EnviroLeach Technologies, Inc. (EVLLF), closed Wednesday's trading session at $0.8776, down 3.84%, on 19,718 volume with 18 trades. The average volume for the last 60 days is 24,556 and the stock's 52-week low/high is $0.4491/$1.8554.

chart

Integrated Ventures, Inc. (INTV)

Promotion Stock Secrets, OTC Markets, Whale Wisdom, The Street, InvestorsHub, Barchart, TradingView, The OTC Reporter, MarketWatch, YCharts, and Investors Hangout reported on Integrated Ventures, Inc. (INTV), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Integrated Ventures, Inc. concentrates on operating subsidiaries in the digital currency sector. The Company’s present crypto portfolio includes BitcoLab – cryptocurrency mining and investing. It also includes Nemesis – manufacturing and sales of mining rigs and equipment. The Company previously went by the name EMS Find, Inc. It changed its corporate name to Integrated Ventures, Inc. in July of 2017. Integrated Ventures has its head office in Huntingdon Valley, Pennsylvania.

In addition, Integrated Ventures’ portfolio includes LoanFunder – the financial platform, designed to integrate with a decentralized and encrypted lending ledger. It offers a secure, efficient, verifiable, and permanent way of storing loan related information.

Integrated Ventures has acquired CreditCalc from ITBS, LLC, a high-end loan management and calculation platform. The expectation is that this stock based transaction will expedite the development lifecycle of Integrated Ventures’ blockchain based lending platform - LoanFunder. CreditCalc permits borrowers and lenders to perform complex calculations related to all kinds of loans. Furthermore, CreditCalc provides users access to the custom credit programs and the ability to shop and compare for different kinds of loan products.

Integrated Ventures entered into an Asset Purchase Agreement (APA) with digiMINE, LLC, earlier this year. This APA is to acquire certain cryptocurrency assets, consisting of 150 assorted ASIC miners and related mining equipment and $175,000 in cash, to be used for the purchase of 145 assorted Antminers by Bitmain Technologies. The remaining capital will be used for the build out for the 5,900 sq ft warehouse facility in Marlboro, New Jersey.

Integrated Ventures announced this past May that it executed the APA to acquire the remaining assets of digiMINE consisting of mining rigs, digital currency, and cash. Pursuant to the executed APA, the total consideration for all the assets being acquired comprises 20,000 Restricted Preferred B Shares, to be issued to digiMINE, LLC.

Recently, Integrated Ventures announced that it entered into a Letter Of Intent (LOI) with Secure Hosting, LLC to acquire certain cryptocurrency equipment comprising 199 revenue generating GPU based mining rigs. With this LOI, the aggregate consideration for the Assets being acquired, comprises 39,679 Preferred B restricted shares, being issued to the selling shareholders of the Secure Hosting, LLC.

Last month, Integrated Ventures confirmed the signing of a Definitive Asset Purchase Agreement (DAPA) with Secure Hosting to complete the earlier announced acquisition of 182 ETH mining rigs, comprising 114 Fuel 8 GPU RX570; 68 Fuel 8 GPU P102; and 182 Power Source Units.

Integrated Ventures, Inc. (INTV), closed Wednesday's trading session at $0.54, down 16.91%, on 57,299 volume with 41 trades. The average volume for the last 60 days is 35,878 and the stock's 52-week low/high is $0.0008/$6.74.

chart

ULURU, Inc. (ULUR)

Innovative Marketing, SmallCapVoice, Zacks, Marketbeat.com, BabyBulls, and TopPennyStockMovers reported earlier on ULURU, Inc. (ULUR), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

ULURU, Inc. is a specialty pharmaceutical company listed on the OTC Markets` OTCQB. It is concentrating on the development of a portfolio of wound management and oral care products. This is to provide patients and consumers improved clinical outcomes by way of controlled delivery utilizing the Company’s inventive Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system. ULURU has its corporate office in Addison, Texas.

The Company’s strategy is to develop and commercialize a customer-centered portfolio of unique wound care products to treat the different phases of wound healing. Furthermore, its strategy involves developing the oral-transmucosal technology and producing revenues through numerous licensing agreements.

Concerning its Nanoflex® Technology, it is a new class of material. The design of it is to optimize the wound bed environment and expedite healing.

ULURU has its Altrazeal® product. It developed and commercializes Altrazeal® - a transforming powder dressing with proprietary Nanoflex® technology, for the management of exuding wounds. Altrazeal® is a scientifically engineered advanced wound dressing designed to incorporate the desired features and benefits of the ideal wound dressing.

Altrazeal® is produced as a sterile powder. It is innovative in application and performance on a moist wound surface. Upon application to a moist wound, the powder interacts with wound exudate and hydrates. Hydration with exudate causes the powder to aggregate irreversibly and form a moist wound dressing, which conforms to the surface of a wound bed and seals the wound.

Altrazeal® has demonstrated potential clinical and economic advantages in manifold chronic and acute wounds. These include diabetic foot ulcers, venous leg ulcers, and geriatric wounds.

ULURU entered into a cooperation agreement with Saraya Co. Ltd. for the registration of Altrazeal® and further cooperation in Japan. In addition, it entered into a licensing and distribution agreement with Juthis Corp. of South Korea. This agreement is for the marketing, sale, and distribution of Altrazeal® in Malaysia and South Korea.

Moreover, ULURU has its OraDisc™A product. The Company developed OraDisc™ A, a novel mucoadhesive, water-erodible disc incorporating 2mg of amlexanox, for the treatment and prevention of aphthous ulcers.

The Company’s OraDisc™ B is a mucoadhesive erodible disc containing 15 mg of benzocaine. It was developed for the treatment of oral pain.

ULURU also has its patented delivery strip for whitening teeth that completely erodes - the OraDisc™ W- Erodible Whitening Strip for Teeth. This proprietary tooth whitening product consists of a laminated bilayer strip that utilizes the OraDisc™ technology.

ULURU, Inc. (ULUR), closed Wednesday's trading session at $0.07, up 6.87%, on 910 volume with 1 trade. The average volume for the last 60 days is 13,227 and the stock's 52-week low/high is $0.02/$0.10.

chart

Generex Biotechnology Corporation (GNBT)

MicroCap Daily, InvestorsHub, OTC Markets, StreetInsider, Stockhouse, Insider Financial, and Zacks reported on Generex Biotechnology Corporation (GNBT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

A biopharmaceutical enterprise, Generex Biotechnology Corporation engages in the discovery, research, development, and financing of new compounds, therapies, diagnostics, delivery systems, and medical technologies. The Company’s main emphasis has been its proprietary technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity utilizing a handheld aerosol applicator. Generex Biotechnology has offices in Burlington, Ontario, and Miramar, Florida. The Company lists on the OTCQB.

Generex Biotechnology has two business focuses. One is implementing an acquisition strategy. The second is financing sponsored clinical trials. The Company is positioning its business as a diversified holding company involved in growing its pipeline of compounds, therapies, treatments, diagnostics, and technologies in all stages in the Food and Drug Administration (FDA) process via accretive acquisitions.

Generex Oral-lyn is an insulin spray for the treatment of Type I and Type II diabetes. The Company states that Generex Oral-lyn is a safe, simple, fast, effective, and pain-free alternative to subcutaneous injections of prandial insulin. It is conveniently delivered to the membranes of the oral cavity through a simple asthma-like device with no pulmonary (lung) deposition.

RapidMist is an advanced buccal drug delivery technology. It consists of a proprietary formulation and a proprietary device design, which can deliver drugs by way of the buccal mucosa safely. Therefore, this eliminates the pain from and need for numerous injections. RapidMist has been shown to have a rapid onset of action with no lung deposition, precise dosage control, easy use and handling, and improved patient compliance.

This past October, Generex Biotechnology announced that its subsidiary, Hema Diagnostic Systems, LLC, entered into an exclusive contract with Imerlab Sociedad Comercial Limitada for the distribution and sale of the Rapid 1-2-3® Hema HIV EXPRESS® diagnostic test in the Republic of Chile. The Chilean Ministry of Health has registered the Rapid 1-2-3® Hema HIV EXPRESS®. It has been approved for sale there.

Imerlab Sociedad Comercial will have the exclusive rights to negotiate with private entities and public institutions for the placement and sale of the product in clinical settings that require fast point-of-care (PoC) testing for HIV, not only in urban hospital and outpatient clinics, but also in parts of the nation that have limited laboratory and testing resources.

In December, Generex Biotechnology announced that its wholly-owned subsidiary, Antigen Express, Inc., entered into a License and Research Agreement with Shenzhen BioScien Pharmaceuticals Co. Ltd. to develop and commercialize the Antigen Express AE37 immunotherapeutic vaccine for prostate cancer in the People’s Republic of China (including Taiwan, Hong Kong, and Macau).

Shenzhen BioScien Pharmaceuticals will pay Generex Biotechnology a non-refundable, up-front license fee of $700,000 USD. With this Agreement, Shenzhen BioScien Pharmaceuticals will also make milestone payments to Generex Biotechnology of $1,000,000 USD each upon completion of the Phase II and Phase III clinical studies of the vaccine and a milestone payment of $2,000,000 USD upon regulatory approval of the vaccine in the territory. In addition, Generex Biotechnology will receive a 10 percent royalty on Net Sales of the product.

Generex Biotechnology will hold an investor conference call at 10:30 a.m. Eastern time on Thursday, January 4, 2018. The purpose of this conference call will be to provide investors with an update on its initiatives and strategic plans. This includes its capital reorganization, its controlling interest in Hema Diagnostic Systems, LLC, the recently announced initiatives of Antigen Express, Inc., the Company’s wholly-owned immuno-therapeutics subsidiary, with Merck Sharp & Dohme B.V. and Shenzhen BioScien Pharmaceuticals Co. Ltd., and the Company’s buccal drug delivery platform technologies.

Generex Biotechnology Corporation (GNBT), closed Wednesday's trading session at $2.10, up 0.96%, on 1,836 volume with 12 trades. The average volume for the last 60 days is 1,621 and the stock's 52-week low/high is $1.89/$4.59.

chart

Jackpot Digital, Inc. (JPOTF)

Penny Stock Tweets, Equities.com, OTC Markets, MarketWatch, Stockhouse, and InvestorsHub reported on Jackpot Digital, Inc. (JPOTF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Jackpot Digital, Inc. is a top electronic table games (ETG) manufacturer and mobile gaming provider for the cruise ship industry and regulated casino industry. The Company specializes in multiplayer gaming products. This includes poker and casino games. Jackpot Digital provides its iGaming products and services to the Business to Consumer (B2C) and Business to Business (B2B) market.

Jackpot Digital has its corporate office in Vancouver, British Columbia. The Company formed in 1999, and was formerly LasVegasFromHome.com Entertainment, Inc. Jackpot Digital’s shares trade on the OTC Markets Group’s OTCQB.

In its B2B model, the Company’s platform partners own the brand and finance the marketing. Typically, Jackpot Digital shares the revenue generated from its games, and charges its platform partners for value added services such as software customization. In its B2C model, Jackpot Digital generates revenue from wagering activities by players.

Additionally, the Company has a set of backend tools for operators to efficiently control and optimize their gaming business. Jackpot Digital has its industry-leading PokerPro ETG (Electronic Table Games) system. Presently, PokerPro is in operation with cruise lines, poker rooms, and casinos around the world.

In March 2012, the Company entered the social gaming market with the launch of Real Vegas Casino. This is a full-featured social casino on Facebook.

Pertaining to mobile gaming on cruise ships, Jackpot Digital provided its premier HTML5 mobile gaming software to Carnival Cruise Lines in November 2014. Jackpot Digital plans on bringing its HTML5 mobile gaming technology from the Cruise Lines industry to the Hotel Industry.

In August 2015, Jackpot Digital purchased the electronic table business unit from Multimedia Games. It consists of industry leading electronic poker tables under the PokerPro® brand name and a varied multi-games table called ProCore™.

Jackpot Digital has its Jackpot Blitz™. This is its proprietary next generation gaming platform. Jackpot Blitz™, via its state-of-the-art technology, offers a first-rate player experience to go with premier operator efficiency, flexibility, as well as profitability. Jackpot Blitz™ features a modern design with a large 84 inch 4K touchscreen. It can accommodate ten players simultaneously.

Earlier this year, Jackpot Digital announced that through a newly incorporated and wholly-owned subsidiary company, Electrium Mining, Inc., it entered into a binding Letter of Intent (LOI )and a 90 day lock-up agreement with International Interactive Ventures of Ramat Gan Israel, and associated companies (Seller Group), as represented by Mr. Andrew Szabo, for the acquisition of all of the Seller Group’s assets associated with cryptocurrency mining, blockchain technology, software and associated Intellectual Property (IP).

The Assets include existing cryptocurrency mining operations situated in a former NATO storage facility in Budapest, Hungary that have grown over the last year to more than 180 cryptocurrency mining rigs. Upon conclusion of the Asset Purchase Agreement, Electrium Mining will be a fully integrated, fully diversified cryptocurrency mining company with existing operations in one of Europe’s lowest cost electricity environments, Budapest, Hungary, with plans to considerably scale-up and spread out into new facilities in the Province of Quebec.

Recently, Jackpot Digital announced that it signed a new Software License and Equipment Lease Agreement with Carnival Corporation & plc. This Agreement outlines terms for the replacement, in phases, of Jackpot Digital’s existing PokerPro Electronic Table Game (ETG) platform with the Company’s next-generation Jackpot Blitz™ ETG on Carnival’s ships, subject to certain terms and conditions.

Jackpot Digital, Inc. (JPOTF), closed Wednesday's trading session at $0.19, up 7.20%, on 1,000 volume with 1 trade. The average volume for the last 60 days is 7,546 and the stock's 52-week low/high is $0.1141/$0.589.

chart

Wrap Technologies, Inc. (WRTC)

Stockflare, Wall Street Pennies, VentureLine, High Rising Stocks, Penny Stock Hub, Stockhouse, Stockwatch, Jet Life Penny Stocks, Simply Wall St, Investors Hangout, Trading View, Investing News Alerts, and Street Insider reported on Wrap Technologies, Inc. (WRTC), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Wrap Technologies, Inc. is an innovator of modern policing solutions. The Company premiered its hand-held BolaWrap™ 100 remote restraint solution at the International Association of Police Chiefs (IACP) October 2017 international conference. The Company’s technology assists law enforcement and military in safely and effectively controlling encounters. Wrap Technologies is based in Las Vegas, Nevada and the Company lists on the OTC Markets Group’s OTCQB.

The BolaWrap 100 is a restraint tool for Police and Military. It can be used early in an encounter between officer and suspect so as to prevent unnecessary escalation and violence. Award winning inventor Mr. Elwood Norris developed BolaWrap™ 100.

The BolaWrap™ 100 is a hand-held remote restraint device. It discharges an eight-foot bola style Kevlar tether to entangle an individual at a range of 10-25 feet. BolaWrap 100 is light and operable by an officer using support hand. Remote restraint helps in controlling subjects. The design of it is to remotely restrain without uncontrolled falls.

BolaWrap 100 features rapid cartridge refresh to support numerous wraps. The design of the product is to safely and effectively control encounters by remotely wrapping a subject's legs, limiting the need for potentially injurious less lethal or lethal force.

Wrap Technologies announced this past June that field testing of the new BolaWrap 100 remote restraint device was scheduled to commence with the Park City (Utah) Police Department. The Company provided Park City with equipment to deploy to identify the best use cases for BolaWrap remote restraint and measure effectiveness as an early engagement tool.

Wrap Technologies has a growing number of product partnerships with high profile agencies designed to ensure the BolaWrap 100 meets customer requirements to restrain noncompliant individuals. Last month, the Company announced it accepted its first international order for its BolaWrap 100 non-lethal remote restraint device.

Today, Wrap Technologies announced that Professor Ronal Serpas, Ph.D. will be advising the Company and its law enforcement customers on integrating the new BolaWrap 100 with effective community policing. As a Police Chief in New Orleans, Nashville and of the Washington State Patrol, Dr. Serpas advanced community policing through implementing Justice and Legitimacy principles in the delivery of police service to successfully lessen crime and build community support. Dr. Serpas was a leader for over two decades in guiding unique changes in use of force policies and investigations of use of force.

Wrap Technologies, Inc. (WRTC), closed Wednesday's trading session at $4.23, down 3.86%, on 11,274 volume with 33 trades. The average volume for the last 60 days is 13,340 and the stock's 52-week low/high is $2.10/$9.00.

chart

Eco Science Solutions, Inc. (ESSI)

Wall Street Mover, ThePUMPTracker, DSR News, Real Pennies, Promotion Stock Secrets, TopPennyStockMovers, Wallstreetlivechat, and Pumps and Dumps reported earlier on Eco Science Solutions, Inc. (ESSI), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Eco Science Solutions, Inc. is an eco-technology Company with its corporate headquarters in Makawao, Hawaii. It provides solutions to the multi-billion-dollar health, wellness, and alternative medicine industry. Eco Science Solutions develops technical solutions - from enterprise software solutions, to consumer applications (apps) for daily use. These solutions energize enthusiasts in their pursuit and enjoyment of building eco-friendly businesses and living healthy lifestyles. Eco Science Solutions’ shares trade on the OTC Markets Group’s OTCQB.

Eco Science Solutions’ key services cover localized communications between consumers and business operators, social networking with like-minded enthusiasts, rich educational content, e-commerce, and fast delivery of products. These all cater to the health-and-wellness lifestyle.

The Company’s brands include Herbo, Fitrix, and pHion Balance. The Herbo app assists consumers in finding products and services that support the intake of alternative medicines for a more naturopathic lifestyle. Herbo has a database of greater than 14,000 alternative medicine locations and delivery services, doctors who provide evaluations, and local shops that sell relevant product.

The Fitrix app is a strong and flexible companion. Fitrix assists users’ in keeping track of their day-to-day fitness routines, dietary habits, and alternative medicine intake. Fitrix users can measure and track anything and everything concerning their health and wellness.

The Company’s pHion Balance underwent development to create nutritional supplements, which support and promote a healthy lifestyle. pHion Balance is centered on developing nutritional supplements that take the guesswork out of supplementing the body in the healthiest way.

Eco Science Solutions will continue to make investments in e-commerce and mobile applications that facilitate B2C (Business-to-Consumer) e-commerce opportunities.

Last year, Eco Science Solutions' main projects focused on continued consumer and enterprise technology investment; continued product formulation and inventory build for distribution; and strategic acquisitions, which provide an accelerated time-frame to obtain market share.

In May of 2017, the Company announced that it signed a Sponsorship, Content Development, and Licensing agreement with Roaring Lion Tours, Inc. Roaring Lion Tours develops inspirational and educational content that further promotes what it believes are the benefits of medical marijuana. This agreement is to develop unique educational content that brings awareness and education to the alternative medicine category.

Eco Science Solutions, Inc. (ESSI), closed Wednesday's trading session at $0.057, up 14.00%, on 39,118 volume with 5 trades. The average volume for the last 60 days is 17,091 and the stock's 52-week low/high is $0.001/$0.38.

chart

The QualityStocks Company Corner

Cyberfort Software, Inc. (OTC: CYBF)

The QualityStocks Daily Newsletter would like to spotlight Cyberfort Software, Inc. (OTC: CYBF).

Cyberfort Software, Inc. (OTC: CYBF) is a cybersecurity technology company specializing in the acquisition and development of security software, content filtering, and ad blocking technology. Headquartered in San Francisco, California, Cyberfort Software is actively dealing with various cyber threats through the development of innovative protection technologies designed for mobile, personal and business tech devices across multiple platforms.

Cyberfort Software, Inc. (OTC: CYBF) is a cybersecurity technology company specializing in the acquisition and development of security software, content filtering, and ad blocking technology. Headquartered in San Francisco, California, Cyberfort Software is actively dealing with various cyber threats through the development of innovative protection technologies designed for mobile, personal and business tech devices across multiple platforms.

Committed to the idea that everyone – from individuals to global corporations – should be able to enjoy a digital future free of malicious attacks robbing them of privacy and security, Cyberfort is working to strengthen its portfolio of cybersecurity IPs and stay one step ahead of cyberthreats. The growing plethora of tech devices enveloping everyday life opens the door to increasing cyberattacks through a stunning array of sophisticated cyberthreats. Protecting organizations and individuals with proactive security postures and protective measures is a key component of Cyberfort’s strategy to develop cybersecurity solutions that are smart, simple and efficient.

The company’s 2016 purchase of Vivio, a provider of pioneering AI content filtering and software protection, underscores Cyberfort’s commitment to cybersecurity. Vivio, an iOS 10 ad blocking app, currently serves over 10,000 unique users across iPhone, iPad and Mac. Vivio makes web browsing better, faster and more satisfying by blocking ads and reducing data usage, which also helps save battery life. Continuous ad blocking rule updates are delivered via an Intellectual Property Cloud-based autonomous engine with ad blocking tracker and malware detection filters.

Cyberfort recently signed a letter of intent to acquire Just Content Software which includes the Just Content app, software and underlying source code. Just Content is an efficacious and multi-functional ad blocking app that safeguards families and businesses with proprietary “Home Safe Filter” and “Business Filter” products. The Just Content app is available on iTunes and protects against unsafe links, adult content, phishing sites and inflammatory hate speech found on the internet, among other potential backdoor attacks and cyberthreats. A due diligence review is underway and a final determination regarding this acquisition is anticipated within weeks.

“Cyberfort aims to become a leader in developing cutting edge ad-blocking protective software that keeps the internet safe for families and business, which in our highly technological and immediate information-access society is a significant concern. Acquiring Just Content furthers our commitment to provide the best and most effective ad-blocking software in the marketplace,” says Cyberfort CEO Daniel Cattlin.

Favorable government regulations promoting tightened web security is a major factor driving adoption of web content filtering solution along with the public’s growing desire to better manage network bandwidth consumption and protect their online security and privacy. Cyberfort’s objective is to protect the data and integrity of personal and business computing assets and defend those assets against any threat or attack. The company’s software also offers symbiotic ad-blocking capabilities to complement its cyber defense effectiveness.

As Cyberfort continues to innovate, the Vivio team intends to leverage the current user base as a sandbox to test and optimize future incremental developments targeting an enterprise suite of tools that can be integrated into sector specific areas of growth. Key areas of focus include mobile device management, bring your own device (“BYOD”), mobile app management and secure mobile browser.

The Cyberfort leadership team is headlined by Cattlin, who offers a new age perspective to the business with expertise in project and asset management and a background in corporate finance. Cattlin brings both the operational and financial understanding to take companies from start-up and early development to expansion and capital growth within a public environment.

Chief Technology Officer Tomas Mistrik helped his team deliver a variety of technological products including the Vivio ad-blocking app for iOS 10 and the Silicon Valley-based Synergykit platform for mobile developers.

Technology Development Manager Krishna Kumar brings more than 10 years of experience in the Information Technology industry where he provided powerful security and ad-blocking measures for companies such as CSC and PayPal India.

Senior Advisor Harish Doddala brings nine years of product management and software engineering experience, delivering results for Cisco, VMware, Oracle, IBM and Siemens.

Cyberfort Software, Inc. (OTC: CYBF), closed the day's trading session at $0.08, up 33.33%, on 17,300 volume with 4 trades. The average volume for the last 60 days is 36,161 and the stock's 52-week low/high is $0.051/$69.00.

Recent News

chart

Lithium Chile Inc. (TSX.V: LITH) (OTCQB: LTMCF)

The QualityStocks Daily Newsletter would like to spotlight Lithium Chile Inc. (LTMCF).

Lithium Chile Inc. (TSX.V: LITH) (OTCQB: LTMCF) is pleased to provide an update on their current drilling program. Based on strong indicators from their first four exploration holes on their Ollague prospect, Lithium Chile has been approved for a fifth hole that will extend the drilling depth from 250 meters to 500 meters.

Lithium Chile Inc. (TSX.V: LITH) (OTCQB: LTMCF), headquartered in Canada, is advancing one of the largest lithium-rich exploration portfolios in Chile consisting of more than 148,000 hectares covering sections of 13 salars or mineral salt flats and one laguna complex. The company’s wholly owned premier properties include 66 square kilometers on the Salar de Atacama, Chile’s largest mineral salt flat which hosts the world’s highest concentration of lithium brine production and is currently the source of about 35 percent of the world’s lithium production. Lithium Chile also owns a significant copper/gold/silver property portfolio consisting of 28,184 hectares over six different properties.

Lithium Chile’s portfolio in the heart of Chile’s lithium-rich salars includes Salar de Coipasa, Salar de Helados, Salar de Atacama, Salar de Turi Salar de Ollague and Salar de Talar. Surface and near surface salt and brine sampling programs on all properties has been completed. To date, samples of high-grade, near-surface lithium brines at each of these projects are showing excellent chemistry of lithium to potassium and lithium to magnesium ratios. Good chemistry is important as it reduces your overall cost of production. Recent geophysical surveys including T.E.M have been completed on 5 of 6 priority targets and data collected to date has been extremely encouraging.

Lithium Chile has identified multiple high-priority brine target areas at its Atacama and Ollague lithium project areas. These areas display the same geophysical characteristics as the lithium-rich aquifers at Salar de Atacama, home to the world’s largest and highest-grade lithium brine producers. Spanning an area of 1,200 square miles, Salar de Atacama is the world’s third largest salt flat behind Salinas Grandes in Argentina and El Salar de Uyuni in neighboring Bolivia. Exploration drilling and resource definition drilling for these target areas are planned for 2018.

“We are delighted with the discovery of such impressive drill target areas at Atacama and Ollague. The results also follow the recent discovery of a 60km2 target area at another of our top Chilean projects – Helados – where we hope to drill in the second quarter of 2018,” stated President and CEO Steve Cochrane. “We have an aggressive multi-project drill program planned for this year, which includes all three of these exciting projects and we look forward to sharing drill results as they come through.”

Global demand for lithium-ion batteries is expected to surpass US$53 billion by 2024 as governments around the world aggressively seek to ban gas-powered vehicles and major automakers invest billions in new technology and electric vehicles powered by lithium-ion batteries. Chile’s mining-friendly jurisdiction offers Lithium Chile a clear, streamlined permitting process that significantly lowers the cost of lithium production to around $1,800/ton as compared to Australia’s $5,000/ton.

Lithium Chile is led by an experienced team with strong Chilean connections. Cochrane’s 36 years of investment industry experience have primarily been focused on the mining sector. During this time, he raised more than US$500 million for a variety of small cap public companies in various businesses and industry sectors including mining.

Terry Walker, P.Geol., vice president of exploration and chief geologist, is a highly experienced geologist. He has spent over 25 years in Chile’s mining industry and is well connected throughout the sector. Walker is co-founder of GeoServicios Piedra Dorada, an exploration and development services company focused on Latin America. He is a Qualified Person for the North American and Australian stock exchanges.

Lithium Chile is well funded and driven by a top-tier team with more than 100 years of combined experience in financing, mining exploration and development in the natural resources sector.

Lithium Chile Inc. (LTMCF), closed the day's trading session at $0.772, up 10.92%, on 443,612 volume with 344 trades. The average volume for the last 60 days is 43,113 and the stock's 52-week low/high is $0.535/$0.97.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) patented DehydraTECH™ drug delivery platform has been confirmed in analysis of a second generation lab study on 40 rats to transport 195 percent more nicotine, reaching peak levels at a four times faster rate to brain tissue than controls (http://nnw.fm/6vu3X).

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body’s gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria’s products and others on the market is the company’s disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the “unusual” taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria’s processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company’s patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria’s lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world’s most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed the day's trading session at $1.91, off by 1.04%, on 350,022 volume with 430 trades. The average volume for the last 60 days is 194,779 and the stock's 52-week low/high is $0.322/$2.54.

Recent News

chart

Zenosense, Inc. (OTCQB: ZENO)

The QualityStocks Daily Newsletter would like to spotlight Zenosense, Inc. (ZENO).

Zenosense, Inc. (OTCQB: ZENO), a healthcare technology company focused on the development and commercialization of the MIDS Cardiac™ hand-held technology for the early detection of heart attack at the Point of Care, is pleased to announce that its MIDS Medical Ltd. joint venture (“MML") has entered a staged funding for the next phase of development of MIDS Cardiac. Also today, the company was featured prominently in an article on the prevalence of heart disease, which showcased ZENO’s development and commercialization of the company’s MIDS Cardiac™ hand-held technology, designed for the early detection of heart attack at the Point of Care.

Zenosense, Inc. (OTCQB: ZENO) (the “Company”) is a healthcare technology developer that participates in transformational, disruptive medical diagnostic projects; particularly handheld devices used at the Point of Care which are displacing slow and expensive laboratory tests.

Zenosense is primarily focused on the development and commercialization of MIDS Cardiac™ through the Company’s joint venture ownership in MIDS Medical Limited (“MML”). MIDS Cardiac is in development as a cost-effective, handheld Point of Care (“POC”) diagnostic device and disposable test strip for the early, rapid detection of suspected acute myocardial infarction (“AMI”, or “heart attack”).

Identification of very low levels of cardiac markers can significantly accelerate critical triage, diagnosis, treatment and disposition of patients reporting chest pain. Cardiac troponin is well documented as the preferred biomarker for diagnosis of AMI, with evidence continuing to demonstrate that high sensitivity troponin is the most powerful prognostic biomarker for the assessment of cardiovascular risk in the general population. However, highly sensitive troponin assays are currently available only on state of the art, central laboratory analyzers. These analyzers are extremely expensive, not generally available at the POC and slow to turnaround results (typically 60 minutes) when time is critical.

True, high-sensitivity devices are not available in smaller handheld devices at the POC, where they are most needed. This is because the optical detection systems generally used in central laboratory analyzers cannot be effectively miniaturized.

MIDS Cardiac uses the patented MIDS technology platform, exclusively available to MML. Instead of using conventional optical detection, MIDS can detect and quantify assay beads nano-magnetically. This means it can be incorporated in a small device expected to achieve highly sensitive detection levels, which can support true high sensitivity cardiac biomarker tests in emergency settings, at the POC.

Harnessing world-class expertise, the MML laboratory is located at the prestigious Sci-Tech Daresbury campus in the U.K., internationally recognized for leading-edge, scientific research and commercial development. MML has the sole rights to the MIDS technology platform, which is protected by patent applications already granted in China and the USA, and applications now in the national phase in all other key geographic areas.

MIDS Cardiac aims to provide a single troponin I or T test within 3 minutes and three panel assay (additional cardiac biomarkers) on a disposable test strip within 8 minutes, using a hand-held device costing a fraction of the price of laboratory analyzers.

MIDS Cardiac should only require a pin prick of blood for a single assay test carried out on an easy-to-use, disposable microfluidic test strip. MIDS Cardiac is being designed to be operated quickly by minimally trained personnel, producing a simple to interpret result in emergency settings, even in the back of an ambulance.

Initial testing of the electronic and microfluidic components of the MIDS Cardiac “Hybrid Strip” system was completed in November 2017. The Hybrid Strip system used for development testing aims to replicate as closely as possible a fully integrated Lab on Chip MIDS test strip set-up. Development testing was conducted on both the assembled hybrid unit and its electronic and microfluidic components separately, focusing mainly on the electronics of the magnetic sensing system.

Testing revealed that a variety of brands and sizes of commercially available assay beads could be magnetically detected in very low quantities, including samples of beads that were previously undetectable. In several instances, the current “limit of detection” appeared to already be at or near to the range advised by MML’s assay consultants as suitable for a high sensitivity troponin assay.

Dr. Nasser Djennati, MML’s Managing Director and Chief Scientific Officer, said; “These results come in at the very high end of detection expectations, even at this Hybrid Strip stage. As we move forward into true Lab on Chip construction, I expect detection levels to improve further still.”

Cardiovascular disease is the leading cause of death in the western world, accounting for more than 17 million deaths in Europe and the United States alone. Nearly 20 million patients each year visit an emergency room with reports of chest pain, with hundreds of millions spent on unnecessary admissions to the hospital. Zenosense Inc. is confident MIDS Cardiac will deliver unparalleled levels of accuracy, speed, reliability, ease of use and cost savings, making it the future device of choice for hospitals, emergency rooms, medical practitioners, paramedics and in low-resource settings.

The MIDS technology is also seen as having a far wider application, with the platform being capable of performing Point of Care immunoassay tests for a vast array of common healthcare concerns, a market projected to be worth $23.7 billion per year worldwide by 2019. The medical testing market as a whole is projected to be worth $53.34 billion by 2021. Zenosense believes the MIDS technology could be the most significant advance in diagnostic testing services in decades.

Zenosense, Inc. (ZENO), closed the day's trading session at $0.3303, up 3.22%, on 234,901 volume with 79 trades. The average volume for the last 60 days is 224,365 and the stock's 52-week low/high is $0.15/$0.895.

Recent News

chart

The Flowr Corporation

The QualityStocks Daily Newsletter would like to spotlight The Flowr Corporation.

The Flowr Corporation, a Health Canada Licensed Producer (LP) of cannabis under the Access to Cannabis for Medical Purposes Regulations (ACMPR), is an emerging Canadian cannabis leader founded by Medreleaf co-founder Tom Flow and a team of industry pioneers, successful start-up executives and top industry scientists. Flowr’s purpose-built cultivation facilities may be the most advanced in the industry, consistently generating high crop yields, delivering premium and ultra-premium cannabis products, and maximizing return on investment. The company also may be an R&D leader as it was selected by the Hawthorne Gardening Division of The Scotts Miracle-Gro Company as its exclusive Canadian cannabis R&D partner.

Flowr’s flagship facility, an 84,000-square-foot campus on seven acres in Kelowna, British Columbia, is engineered to grow premium cannabis in rooms that meet pharmaceutical industry production standards for cleanliness. This, along with exacting protocols designed by the Flowr team, enables Flowr to grow cannabis that meets Health Canada’s stringent standards without treating it with the taste- and smell-killing gamma irradiation that most other producers have to use to clean their product. Irradiating the plant – a process similar to pasteurizing food – impairs many of the important terpenes that provide the positive effects, flavors and scents of cannabis while strengthening unpleasant terpenes. Flowr’s products may deliver a better user experience, thus commanding premium prices.

Flowr’s cultivation facilities, built with proprietary, patent-pending systems, are designed to deliver yields targeted at 450 grams per square foot by the end of 2022, which is three times more efficient than the industry average of approximately 150 grams per square foot. By optimizing yield, the Company may produce significantly more cannabis flower on a smaller footprint than other producers, thus generating far high revenue per square foot and keeping costs much lower, leading to higher margins. The Kelowna facility is presently 20 percent operational with the remaining 80 percent slated to come online by early 2019. It is expected to produce up to 14,000 kg of premium, non-irradiated cannabis flower in 2019. With further enhanced yields and planned expansion of production facilities on the campus, Flowr will reach a total capacity of 60,000 kg annually in 2022.

Leading Flowr’s cultivation program is industry pioneer, company co-founder and Flowr president Tom Flow. Flow is widely recognized for his cannabis thought leadership and expertise building and operating cannabis cultivation facilities. Flow also co-founded MedReleaf and designed, built and set up SOPs for their flagship Marcum cultivation facility. Marcum has continued to be perhaps the most productive facility in the country prior to the Flowr flagship facility. Long one of Canada’s most efficient and profitable LPs, MedReleaf was acquired by Aurora for approximately C$3 billion. Flow and his team have designed and built a total of 17 cultivation facilities and secured three producer’s licenses under various Canadian regulatory regimes.

In March 2018, Flowr and the Hawthorne Gardening Division of The Scotts Miracle-Gro Company – a world leader in lawn and garden products – announced an exclusive strategic R&D alliance. After evaluating numerous Canadian LPs, Hawthorne chose to partner with Flowr based on the experience and expertise of the company’s cultivation and R&D teams and the company’s advanced growing capabilities.

Hawthorne will fund the construction of a 50,000-square-foot R&D facility that is integrated into Flowr’s Kelowna campus. This facility is North America’s first dedicated cannabis R&D facility focused on advancing cultivation techniques and systems. The facility will support researchers from both organizations and combine laboratories, indoor and greenhouse grow suites, training areas and genetics breeding areas in a single building. It is expected to open in early 2019. In addition to helping Flowr maintain its competitive advantage in cultivation, the company’s R&D program will keep it on the cutting edge of cannabis innovation.

Flowr is entering the market with three different brands to meet the growing demand for premium, non-irradiated cannabis in the medicinal and adult use markets:

  • FlowrRx, featuring premium quality medicinal cannabis that enables patients to live better, fuller lives. A dedicated Client Services team will provide patients with personalized support while an R&D team develops innovative flower strains and premium products targeted to specific conditions. Patient well-being is considered at every stage of the process – from genetic selection to harvest, trimming and curing techniques. FlowrRx and its team of passionate scientists and leading cultivation specialists are dedicated to advancing the scientific understanding of cannabis.
  • Flowr is the company’s premium recreational adult-use brand featuring an active, West Coast-inspired lifestyle for the cannabis connoisseur and enthusiast market. Through the continuous innovation of procedures and practices, Flowr’s talented team of experts is crafting premium products that deliver unparalleled experiences.
  • Ace Valley, an exclusive partnership with top-selling Ontario craft beer company Ace Hill, will bring Flowr’s premium product to the millennial and casual adult-use markets under the Ace Valley brand.

Flowr recently signed a Memorandum of Understanding with the British Columbia Liquor Distribution Branch, the province’s sole legal wholesaler of non-medical cannabis, to supply premium and ultra-premium flower to the province’s retail outlets. The company has agreements with several major medical distributors and is in discussions about retail distribution with additional provinces where it believes it can obtain prices commensurate with the quality of the Flowr products. The company is also evaluating other market opportunities including export.

Flowr is poised to become the pre-eminent indoor premium cannabis grower in Canada and one of the country’s top five LPs. The company’s focus on yield, quality and price point and its team’s ability to grow at scale should drive high margins, significant growth and strong return on investment.

Recent News

SinglePoint, Inc. (OTCQB: SING)

The QualityStocks Daily Newsletter would like to spotlight SinglePoint, Inc. (SING).

SinglePoint Inc. (OTCQB: SING) announces an additional investment into StakeHaul, the No. 1 peer-to-peer betting application. StakeHaul offers a unique way for individuals to bet on anything, from the NFL week one matchups to who will win your weekend’s round of golf.

SinglePoint, Inc. (OTCQB: SING) is a diversified holding company with operations in multiple industries and verticals including two high-performing market sectors: legal cannabis and cryptocurrencies. SinglePoint has grown from a full-service mobile technology provider to a recognizable brand with a diverse portfolio of undervalued subsidiaries with multiple revenue streams.

SinglePoint is researching opportunities where it can be an active participant by influencing the strategy and direction of high-potential companies whose verified assets offer attractive possibilities for shareholders. The company is guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital.

SinglePoint is bullish on the cannabis industry, bitcoin and blockchain technologies, which is evident in its recent acquisitions and joint-venture announcements. Recent SinglePoint key highlights include:

  • A joint venture with Smart Cannabis Corporation (OTC: SCNA) to license and market Smart Cannabis’ SMART APP. SMART APP enables cannabis growers to measure all aspects of cultivation, from soil nutrient levels to watering cycles and carbon dioxide content in the air. SMART APP will integrate SinglePoint’s bitcoin payment solution to enable growers to process safer and more secure transactions.
  • A joint venture with Global Payout (OTC: GOHE) will build on existing financial technology solutions developed by SinglePoint and Global Payout’s subsidiary MoneyTrac Technology, Inc., to fully optimize the delivery of mobile payment applications for domestic and international organizations.
  • A joint venture with AppSwarm (OTC: SWRM) to start development on a proprietary delivery application that will enable licensed cannabis delivery services and licensed dispensaries to safely make in-home cannabis deliveries.
  • Signed original “Shark Tank” member Kevin Harrington as company spokesman for an innovative, compatible virtual wallet to store any type of cryptocurrency. Harrington recently finished shooting a new national ad campaign featuring SinglePoint and the virtual wallet’s secure method of storing cryptocurrencies.
  • Entered into a letter of intent to acquire 100 percent of Bitcoin Beyond, a premier platform that enables merchants to accept bitcoin payments using existing web-enabled point-of-sale devices.
  • Through SING subsidiary, SingleSeed, the company will soon offer a proprietary cryptocurrency solution that links both cannabis merchants and consumers who seek to take advantage of bitcoin-powered transactions using debit and credit cards. In addition to making bitcoin-backed card purchases possible, the solution enables cannabis dispensaries to digitally track and manage their product inventories, performing tasks like uploading product data, photos and descriptions. The system deducts items automatically from a dispensary’s product listings when a purchase is made. While this fully KYC-AML compliant point-of-sale platform can be utilized for any other retail setting, it will fill a critical need in the underbanked cannabis industry as it continues to seek non-cash payment solutions outside of traditional banking circles.

SinglePoint CEO and founder Greg Lambrecht leads the company in its mission to capture opportunities through an aggressive expansion strategy across a broad range of assets. Lambrecht oversees all company operations including investor relations, leadership of the board of directors, and daily business activities. As the founder of PCI, a leading consumer product distribution company, Lambrecht negotiated agreements with the nation’s largest retail outlets and led PCI through a NASDAQ listed IPO, raising $10 million.

Eric Lofdahl, SinglePoint’s chief technology officer, has more than 20 years of experience in the technology sector including positions in software development, program management, complex system integration and engineering process definition. Prior to SinglePoint, Lofdahl worked at the Boeing Company where he led a team that successfully developed advanced wireless and satellite data products based on commercial technology for the U.S. Air Force.

SinglePoint President Wil Ralston is well known for his successful track record of building and maintaining great relationships with clients. Ralston graduated cum laude from the WP Carey School of Business at Arizona State University with a degree in Global Agribusiness and a specialization in Professional Golf Management. He is currently recognized by the Professional Golfers Association of America (PGA) as a Class A Professional.

SinglePoint, Inc. (SING), closed the day's trading session at $0.031, off by 0.32%, on 3,896,154 volume with 178 trades. The average volume for the last 60 days is 5,322,811 and the stock's 52-week low/high is $0.0235/$0.133.

Recent News

chart

Youngevity International, Inc. (NASDAQ: YGYI)

The QualityStocks Daily Newsletter would like to spotlight Youngevity International, Inc. (YGYI).

Over 20 years ago, Youngevity International, Inc. (NASDAQ: YGYI) was founded around one central question: How can we live younger, longer? Since then, YGYI has prided itself on developing the highest quality and most well-researched nutritional products. Now a leading omni-direct lifestyle company, YGYI is putting people on a holistic path to better health.

Youngevity International, Inc. (NASDAQ: YGYI) is a leading omni-direct lifestyle company offering a hybrid of the direct selling business model that includes e-commerce and the power of social selling. Among the Top 100 Global Direct Selling Companies, Youngevity offers products from the six top selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, and a range of innovative services. Created through the 2011 merger of Youngevity Essential Life Sciences with Javalution® Coffee Company, today’s Youngevity International Inc. is a virtual worldwide Main Street of products and services under one corporate entity that supports a healthy and empowered lifestyle.

Youngevity International is dedicated to improving lifestyles through the universal desires of vibrant health and flourishing economics. Catering to health-conscious consumers, Youngevity believes that combining the best of the direct selling industry with the fundamentals and capabilities of a traditional business model will maximize shareholder value. The company’s Nutritional, Lifestyle and Telecommunications products and services are distributed through a global network of Preferred Customers and Distributors.

Youngevity’s wholly owned CLR Roasters LLC business line offers quality branded and private label coffee to retail stores, office coffee services, hospitality, food services, distributors, convenience, petrol stores and vending businesses. Today, CLR Roasters is the largest coffee provider for cruise lines in North America and the second largest roaster in the state of Florida. Producing a consistent premium product with superior taste, CLR Roasters has earned numerous certifications that demonstrate the company’s commitment to the craft of providing the highest quality coffee products using the best practice standards available.

Youngevity, operating in the direct-selling channel, is rapidly expanding its product and distributor base through acquisitions and mergers under an innovative concept called “the Network Cloud” that provides other direct selling companies with a home base. The company’s YoungevityGO2 mobile distributor app, a new technology-driven web platform supporting expansion of global e-commerce and social selling platforms, is available on Google Play and the App Store. In addition to the Network Cloud concept, Youngevity International owns CLR Coffee Roasters which operates a traditional coffee roasting business offering a JavaFit® gourmet product line that vertically integrates with Youngevity and its growing network of direct marketers.

Youngevity International offers more than 1,000 high quality, technologically advanced products under the following categories:

  • Health and Nutrition
  • Home and Family
  • Food and Beverage
  • Spa and Beauty
  • Fashion
  • Essential Oils
  • Photo and scrapbooking
  • Services for Home and Business

Youngevity International Inc. has compiled a best-in-class management team with a strong track record of success in private and public companies. Steve Wallach, CEO, has nearly two decades of sales and network marketing experience and has successfully guided Youngevity International Inc. to become an international, publicly-traded direct marketing company positioned for worldwide growth. Dave Briskie, president and CFO, has shepherded the company’s development into a fully vertical coffee roasting and distribution company that owns the direct marketing brand JavaFit® and the retail brand, Café La Rica.

Youngevity has also attracted a stunning group of Brand Evangelists who endorse its products. Among these are actress, author and well-known health and wellness activist Marilu Henner; former NBA basket player, Mike “Stinger” Glenn; former NFL wide receiver Drew Pearson; “Greatest Natural Bodybuilder in the World” Gene Nelson; and WNBA champion, Olympic gold medalist Delisha Jones.

Youngevity International, Inc. (NASDAQ: YGYI), closed the day's trading session at $3.7575, off by 4.87%, on 4,368 volume with 48 trades. The average volume for the last 60 days is 18,206 and the stock's 52-week low/high is $3.1674/$6.75.

Recent News

chart

CytoDyn Inc. (OTCQB: CYDY)

The QualityStocks Daily Newsletter would like to spotlight CytoDyn Inc. (CYDY).

CytoDyn Inc. (OTC.QB: CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, announces its plan to develop PRO 140 (leronlimab) as a therapy for triple-negative breast cancer that has metastasized as its initial cancer indication. 

CytoDyn Inc. (OTCQB: CYDY) is a biotechnology company focused on the clinical development and potential commercialization of a new class of HIV/AIDS therapeutics or viral-entry inhibitors intended to protect healthy cells from viral infection. The company’s pipeline includes its lead product, PRO 140 for multiple indications among which are human immunodeficiency virus (HIV), graft-versus-host disease (GvHD), colon cancer, and multiple sclerosis (MS), each in various stages of development. CytoDyn first approval is focused on HIV indications for two different HIV populations.

PRO 140 is a humanized monoclonal antibody directed at CCR5, a molecular portal that HIV uses to enter T-cells. PRO 140 works by blocking the predominant HIV (R5) subtype entry into T-cells by masking this required co-receptor, CCR5.

CytoDyn has completed one pivotal phase 3 clinical trials of PRO 140 use in combination with current drugs for population that has limited treatment options. PRO 140 is also currently in another phase 3 (investigative trial) for a second approval for another HIV population. HIV continues to be a major global public health issue. There is no cure for the disease that has claimed more than 35 million lives to date, according to the World Health Organization (“WHO”). In 2017, 940,000 people around the world died from HIV-related causes. There were approximately 36.9 million people living with HIV at the end of 2017 with 1.8 million people becoming newly infected during that same year. The WHO estimates there were 21.7 million people globally receiving antiretroviral therapy (“ART”) in 2017.

HIV targets the immune system and weakens the body’s defense systems against infections and some types of cancer. As the virus destroys and impairs the function of immune cells, infected individuals gradually become immunodeficient which results in increased susceptibility to a wide range of infections, cancers and other diseases that people with healthy immune systems can fight off. The most advanced stage of HIV infection is Acquired Immunodeficiency Syndrome (AIDS), which can take from 2 to 15 years to develop depending on the individual.

PRO 140 functions by blocking the HIV co-receptor CCR5, a molecular portal HIV uses to enter T-cells, thus preventing the HIV virus from entering the cell. CCR5 is a protein located on the surface of white blood cells that normally serves as a receptor for chemicals that attract immune cells to the site of inflammation. Clinical trials to date indicate PRO 140 does not interfere with these normal CCR5 functions. Results from phase 1 and phase 2 human clinical trials have shown PRO 140 significantly reduces viral burden in people infected with HIV. Importantly, in a recent phase 2b clinical trial, PRO 140 demonstrated it can allow a subset of R5 strain of HIV population to replace their current HIV regimen (Highly Active Antiretroviral Therapy or “HAART.”) by a simple sub-cutaneous self-injectable dose of PRO 140 which is administered once a week. Some of those patients have received PRO 140 as their only therapy for almost four years.

The PRO 140 antibody appears to be a powerful antiviral agent with hardly any side effects, toxicity. More than 500 patients have used PRO 140 in clinical trial and no resistance has ever been developed in any patients including patients in monotherapy of PRO 140 for almost four years.

PRO 140, which is taken as an easy-to-use, weekly, subcutaneous self-administered dose, has almost no side effects or toxicity with no report of any serious adverse event related to PRO 140 in more than 500 patients in eight different clinical trial.

As we indicated earlier patients given PRO 140 showed no drug resistance on monotherapy for some almost four years while 76% of HAART patients developed a resistance to some portion of the lifetime drug regimen. Patient compliance with HAART is also the main reason why only 35% of HIV patients in US reporting complete viral load (VL) suppression which is VL<50 cp/mL.

In addition to its research into the powerful potential of PRO 140 for use in HIV patients, CytoDyn is pursuing PRO 140 as a therapeutic anti-viral agent in other non-HIV indications that could benefit from PRO 140’s ability to block CCR5. These immunologic indications include new reactions to cancer, transplantation rejection, autoimmune diseases and chronic inflammation such as Multiple Sclerosis. The company sees the significant potential for multiple pipeline opportunities for PRO 140.

The U.S. Food and Drug Administration has designated PRO 140 as a “fast track” product for HIV and granted Orphan Drug Designation to it for the prevention of GvHD in transplant patients. CytoDyn has initiated its first clinical trial with PRO 140 in an immunological indication for GvHD in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are undergoing bone marrow stem cell transplantation. The company is also investigating PRO 140 in animal models of cancer progression and autoimmunity with positive results and has published its animal study results in GvHD in peer-reviewed journal.

CytoDyn president and CEO Nader Z. Pourhassan, Ph.D. joined the company in 2008 and is credited for purchasing PRO 140 from Progenics in 2012 and has taken a new path to approval for the product. He is the co-inventor of monotherapy path for PRO 140. He has taken PRO 140 development from phase 2 to Completed successful phase 3 in about four years. He now has more than 10 years of drug development experience and has overseen the rapid clinical development of PRO 140 as a therapy for HIV into two phase 3 for two different indications. He also initiated PRO 140 first immunological indication in GvHD (currently in phase 2). He is also involved in preclinical and clinical development of PRO 140 in additional immunological indications.?Dr. Pourhassan, who has more than 20 years of business development experience, has led CytoDyn’s capital market activities since joining the company in 2008. He received his Bachelor of Science from Utah State University, Master of Science from Brigham Young University, and his Ph.D. in Mechanical Engineering from the University of Utah and is the author of three books.

CytoDyn Inc. (CYDY), closed the day's trading session at $0.661, off by 4.89%, on 301,817 volume with 96 trades. The average volume for the last 60 days is 341,398 and the stock's 52-week low/high is $0.40/$0.836.

Recent News

chart

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

With the release of its Q2 2018 results, a sterling performance by The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) is on display (http://nnw.fm/YOj9O).

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed the day's trading session at $4.94, off by 8.41%, on 2,579,719 volume with 5,157 trades. The average volume for the last 60 days is 247,349 and the stock's 52-week low/high is $2.784/$7.565.

Recent News

chart

Cannabis Strategic Ventures, Inc. (OTC: NUGS)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Strategic Ventures, Inc. (NUGS).

Cannabis Strategic Ventures, Inc. (OTC: NUGS) announces an increased commitment to cannabis sector brands and innovators through the development of a proprietary branding and partnership model for the fast-growing Industry. Over the coming months, the Company will continue to develop multiple proprietary brands as its primary investment focus. Also today, NetworkNewsWire released a report on the company detailing how NUGS this morning announced its increased commitment to cannabis industry brands and innovators through the development of a proprietary branding and partnership model for the cannabis industry. To view the full press release, visit: http://nnw.fm/hk6Fu. Additionally, today NUGS was the subject of an article discussing the company’s ongoing expansion of its diverse portfolio by moving into the pet care arena through its acquisition of The Asher House Pet CBD brand from The Asher House LLC, as detailed in a recent news release (http://nnw.fm/hA2gv).

Cannabis Strategic Ventures, Inc. (OTC: NUGS), headquartered in Los Angeles, California, is focused on supporting entrepreneurial growth within the fast-growing legal cannabis sector. Through a selective portfolio of subsidiaries, Cannabis Strategic Ventures offers outsourced personnel solutions tailor-made to match the growth dynamics of cannabis cultivators, manufacturers, dispensaries and other cannabis marketplace participants. The company also pursues investment opportunities in the areas of real estate, cultivation, extraction, distribution, packaging, dispensary operations, and branded products within the cannabis space.

The legalization of adult-use sales in California is expected to create nearly 99,000 cannabis industry jobs in the state by 2021, representing about a third of all cannabis jobs nationwide, and 146,000 jobs overall when indirect and induced efforts are considered, according to Arcview Market Research. By 2021, direct cannabis industry employment will top 291,500 FTE jobs, with a total employment effect of nearly 414,000 FTEs across all legal cannabis states, according to the report.

Cannabis Strategic Ventures believes its staffing capabilities will be in a similar state of demand. The company in April 2018 completed a definitive agreement to acquire Worldwide Staffing Group, Inc., which booked approximately $1.5 million in revenues in 2017.

Worldwide will operate within Cannabis Strategic Ventures as an independent and separate wholly owned subsidiary providing strictly non-cannabis related employment and staffing services. As Worldwide continues to expand its operations in general clerical and administrative, marketing, accounting, and other verticals, Cannabis Strategic Ventures will leverage the subsidiary’s expertise to expand its business operations further into the cannabis staffing arena, with an emphasis on the California markets.

Cannabis Strategic Ventures’ BudHire™ subsidiary is an outsourced employment service specifically designed to meet the needs of growing cannabis-related business operations, utilizes a proven recruiting formula to match the most qualified candidates to a broad spectrum of cannabis-related jobs. Under the BudHire™ brand, Cannabis Strategic Ventures offers temporary, seasonal, permanent staffing solutions, as well as professional employment organization services and human resources consulting to the cannabis industry.

Cannabis Strategic Ventures portfolio also includes Pure Applied Sciences Inc. and its brand “PureOrganix™,” a line of high quality concentrate, organic and pure cannabis oils that conform with Current Good Manufacturing Practices (cGMP) and meet FDA guidelines for Active Pharmaceuticals Products (API). The acquisition includes all intellectual properties, including formulations and technologies, and related accessories of Pure Applied Sciences.

Cannabis Strategic Ventures Pure Applied Sciences subsidiary, has a cannabis concentrate extraction services agreement with CP Logistics LLC (“CPL”), a wholly owned U.S. subsidiary of Sunniva Inc. (CSE:SNN) (OTCQX:SNNVF). Under this agreement, CPL will perform white label services producing high quality, ultra-purified cannabis extracts out of its Sun-Oil Facility in Cathedral City, California, for Pure Applied Sciences under the Pure Organix brand name.

The management team at Cannabis Strategic Ventures believes there is incredible opportunity to carve-out and control specific industry niches, to create unique cannabis consumer branded products, and to expand into other sub-sectors of the cannabis marketplace.

Cannabis Strategic Ventures, Inc. (NUGS), closed the day's trading session at $4.01, off by 10.29%, on 150,394 volume with 435 trades. The average volume for the last 60 days is 89,387 and the stock's 52-week low/high is $0.031/$7.13.

Recent News

chart

Sugarmade, Inc. (OTC: SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (SGMD).

One of the largest publicly traded hydroponics supply companies, Sugarmade, Inc. (OTC: SGMD) is joining the ranks of savvy businesses that have chosen to enter the burgeoning hemp market. Last year, the U.S. hemp industry topped out at an impressive $820 million in revenue, and that total is expected to reach more than $1 billion by the end of 2018, with a 14 percent compound annual growth rate forecast through 2022.

Sugarmade, Inc. (OTCQB: SGMD) one of the largest publicly traded hydroponics supply companies moving into the industrial hemp space, is a product and brand marketing company investing in products and brands with disruptive potential. Sugarmade’s brands include: ZenHydro.com; CarryOutSupplies.com; and BudLife. Headquartered in Monrovia, California, a city within Los Angeles county, Sugarmade has various business operations in diverse marketplaces including packaging and paper goods for various industries, agricultural supplies.

Sugarmade has expanded into the European hydroponics supply market with a growing base of orders taken through Amazon UK. Over the past few financial quarters, Sugarmade has seen revenue growth patterns expand geographically. As recently as mid-2017, the majority of hydroponic-related revenue growth was seen from California and other West Coast marketplaces, however growth is becoming more geographically dispersed among U.S. states where legalization has eased restriction. This movement into the United Kingdom further expands the base of geographic growth areas for Sugarmade.

Sugarmade recently launched a new corporate initiative in the booming industrial hemp and CBD, committing up to $1 million in capital over the next 12 months to invest in Hempistry, Inc., a privately held Nevada corporation. Hempistry has begun planting an ultra-high cannabidiol (CBD) industrial hemp strain on a land option it holds on 23,000 acres of prime Kentucky farmland. The strain of industrial hemp being grown by Hempistry is ultra-rich in CBD but contains less than 0.3 percent of THC, the psychoactive ingredient found in cannabis. The U.S. hemp industry is expected to produce well over $1 billion in revenues in 2018, with a compound annual growth rate of 14 percent through 2022, according to the Hemp Business Journal.

Demand for industrial hemp and products derived from hemp is soaring, with no let-up in sight, which the company sees as a “tremendous opportunity to become a supplier to this fast-growing sector,” said Chairman and CEO Jimmy Chan, who is also an advisor and minority shareholder of Hempistry.

Sugarmade’s investment into the market for high-CBD hemp is expected to be highly accretive for common shareholders in two ways. First, Sugarmade’s investment will be in the form of common shares in Hempistry allowing Sugarmade common shareholders to possibly benefit from any future initial public offering of Hempistry. Second, Sugarmade is expected to sign a supply agreement with Hempistry for cultivation supplies, which would be additive to corporate revenues.

Sugarmade has also completed a master market agreement with industry leader BizRight Hydroponics, Inc., a leading marketer and manufacturer of cannabis and hydroponic growth supplies, which offers a range of hydroponics-related products including: HPS grow lights, electronic ballasts, HPS bulbs, nutrient mixes, environmental control products, pH measurement and calibration solutions and storage products. BizRight operates the ZenHydro.com website and other e-commerce properties and sells various products to distributors and retailers. BizRight is expected to produce in excess of $30 million in revenues during 2017, with substantial growth expected for 2018.

Sugarmade division CarryOutSupplies.com, the leader in paper and plastic take-out supplies, serves nationwide customers by offering a wide array of high quality products that are cost-efficient, custom-made and delivered on time. This business unit currently serves 2,000 quick service restaurants, garnering from 30-40 percent of the market share. Sugarmade plans to expand operations via the addition of market share and the introduction of new product offerings.

Management

CEO Jimmy Chan is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, and international manufacturing and importation. He is also the founder of CarryOutSupplies.com, a company that revolutionized the custom-printed paper supplies subsector of the quick service restaurant industry, which merged with Sugarmade in 2014.

Arman Tabatabaei serves as operations consultant, providing high-level, day-to-day strategic guidance and tactical operational supervision for all aspects of the corporation’s business. He is an expert at data collection and analysis relative to resource management, risk forecasting and profit and loss management.

Sugarmade specializes in growing and acquiring innovative brands to maximize value for company employees, shareholders and other stakeholders. Sugarmade believes its future is very bright as the company expands operations within the cultivation sector and rapidly increases its revenue base.

Sugarmade, Inc. (SGMD), closed the day's trading session at $0.108, off by 13.60%, on 2,388,049 volume with 252 trades. The average volume for the last 60 days is 968,630 and the stock's 52-week low/high is $0.028/$0.43.

Recent News

chart

GTX Corp (OTC: GTXO)

The QualityStocks Daily Newsletter would like to spotlight GTX Corp (GTXO).

GTX Corp (OTCBB: GTXO) (“the Company”), an Internet of Things (IoT) solutions provider in the wearable location and wandering assistive GPS technology business, announced today it has received a new contract from Edwards Air Force Base (AFB) for additional units of its Personnel, Equipment Tracking System (P.E.T.S.), which is a lightweight, mobile, non-cellular, encrypted GPS technology platform designed to track personnel and equipment.

GTX Corp (OTC: GTXO), a For Profit For Purpose company, designs, manufactures and commercializes various products and services in the GPS tracking and monitoring business. Operating domestically and internationally, via two subsidiaries engaged in the internet of things (IoT) and wearable technology industry. Founded in 2002 and headquartered in Los Angeles, California, the company is a pioneer in Smart GPS, cellular and Bluetooth Low Energy (BLE) tracking technology, offering complete, end-to-end tracking solutions through a proprietary IoT enterprise monitoring platform – the IoT Machine to Machine platform – backed by state-of-the-art hardware, software and connectivity solutions, patents and software algorithms.

Operating under the motto “We Put the ‘Where’ in Wearable Tech,” GTX’s main goal is to keep its customers connected to who and what matters most, with each of its patented tracking technologies providing real-time location coordinates on a map via a personalized portal. The company prides itself on offering not only technologies, but also effective solutions that provide safety, security and peace of mind by helping customers locate their loved ones or lost valuable items.

With a portfolio that includes more than 80 patents filed and issued and with products and services available in 35 countries, GTX’s tracking solutions use the latest in miniaturized, low-power GPS, mobile, RF and BLE technology, that can integrate seamlessly with multiple consumer products, enterprise and military applications. The company became a U.S. Military contractor in 2017 and is already developing asset and human tracking technology for the U.S. Air Force. Its list of customers also includes public health authorities and municipalities, emergency and law enforcement, NGOs, private companies, public and private senior care homes, and consumers.

The company’s flagship product is the award-winning GPS SmartSole®, the world’s first invisible wearable tracking device created specifically for people at risk of wandering, becoming lost or disoriented, including patients with Alzheimer’s, autism, dementia, traumatic brain injury and other cognitive problems. According to the World Alzheimer Report 2013 (http://nnw.fm/mrcV2), there are more than 100 million people worldwide who need constant care and monitoring because of a cognitive disorder, and their number is expected to rise to 277 million by 2050. Due to its hidden location – inside a shoe insert, the device can also be used by people undercover or at risk of kidnapping, such as government agents, military personnel, law enforcement, journalists, corporate executives, etc.

Other tracking devices designed and commercialized by the company for civilian or military use include:

  • Take-Along Tracker 3G: A powerful mini-tracking device with GPS, 2G and 3G GSM data and voice capabilities, as well as a motion sensor and sleep mode. The device can be easily attached to a keychain, lanyard, dog collar, pocket, bag or plush toy for a discreet but advanced tracking solution.
  • Invisabelt: Designed for children, this slim GPS tracker hidden inside a small waistband belt has a battery life of up to two days and is a great solution for parents who want to monitor their children’s location at all times.
  • Track My Workforce: An easy and cost-effective solution that allows businesses to track and monitor their mobile workforce. The app is available for both Android and iOS systems, and allows employers to monitor their workforce from a single company account.
  • P.E.T.S. -Personnel Equipment Tracking System: Currently in use at the Edwards Air Force Base, this tracking system allows real-time monitoring and surveillance of personnel and assets and has a 200+ square mile coverage. Solar powering capabilities and extend battery life allow the tracker to be used in areas without existing power sources.
  • GPS Rifle Tracker: The company’s smallest GPS tracker, designed to withstand shocks and water submersion due to its robust, military standard enclosure, can be mounted on any AR15 platform picatinny rail to detect weapon discharge, track weapons and inventory, and send time and location alerts.

Led by a management team with solid experience in wearable technology, IoT, consumer electronics, mobile and technology licensing, as well as finance and the footwear industry, GTX plans to leverage its core technology platform to reach new verticals via licensing agreements and strategic partnerships, and to monetize its intellectual property portfolio. The monetization campaign kicked off in 2017 has already identified 100 companies that could become licensees. Besides military and law enforcement, the company also eyes the biometrics market, home health, medicare and insurance and other security applications for potential uses of its IoT platform and tracking technology.

GTX currently has 15 domestic and international distributors, subscribers in 35 countries and more than 700 online affiliates. With multiple revenue streams, several consecutive years of double-digit revenue growth and a strong pipeline of lucrative commercial products, GTX is uniquely positioned to become a leading provider of tracking solutions on this growing multi-billion-dollar market.

GTX Corp (GTXO), closed the day's trading session at $0.05, off by 15.97%, on 555,628 volume with 48 trades. The average volume for the last 60 days is 33,794 and the stock's 52-week low/high is $0.044/$0.6675.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.